A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

NCT00549900 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)

Sponsor

GlaxoSmithKline